Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells

Journal of Functional Foods

Volumn 23, Issue , 2016, Pages 230-240

  Lammi, Carmen ^a   Zanoni, Chiara ^a,b   Calabresi, Laura ^a,b   Arnoldi, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Bioactive peptides; HepG2 cells; HNF1 alpha; Lupinus; PCSK9; Plant proteins

Indexed keywords

EID: 84959513979     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2016.02.042     Document Type: Article

References (50)

1. Arnoldi A., Boschin G., Zanoni C., Lammi C. The health benefits of sweet lupin seed flours and isolated proteins. Journal of Functional Foods 2015, 18:550-563.
2. Awan Z., Seidah N.G., MacFadyen J.G., Benjannet S., Chasman D.I., Ridker P.M., Genest J. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: The JUPITER trial. Clinical Chemistry 2012, 58(1):183-189.
3. Bähr M., Fechner A., Kiehntopf M., Jahreis G. Consuming a mixed diet enriched with lupin protein beneficially affects plasma lipids in hypercholesterolemic subjects: A randomized controlled trial. Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition 2015, 34(1):7-14.
4. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., Asselin M.C., Hamelin J., Varret M., Allard D., Trillard M., Abifadel M., Tebon A., Attie A.D., Rader D.J., Boileau C., Brissette L., Chrétien M., Prat A., Seidah N.G. NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. The Journal of Biological Chemistry 2004, 279(47):48865-48875.
5. Bertoglio J.C., Calvo M.A., Hancke J.L., Burgos R.A., Riva A., Morazzoni P., Ponzone C., Magni C., Duranti M. Hypoglycemic effect of lupin seed gamma-conglutin in experimental animals and healthy human subjects. Fitoterapia 2011, 82(7):933-938.
6. Boschin G., Scigliuolo G.M., Resta D., Arnoldi A. Optimization of the enzymatic hydrolysis of Lupin (Lupinus) proteins for producing ACE-inhibitory peptides. Journal of Agricultural and Food Chemistry 2014, 62(8):1846-1851.
7. Braithwaite M.C., Tyagi C., Tomar L.K., Kumar P., Choonara Y.E., Pillay V. Nutraceutical-based therapeutics and formulation strategies augmenting their efficiency to complement modern medicine: An overview. Journal of Functional Foods 2014, 6:82-99.
8. Cameron J., Ranheim T., Kulseth M.A., Leren T.P., Berge K.E. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008, 201(2):266-273.
9. Dong B., Li H., Singh A.B., Cao A., Liu J. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. The Journal of Biological Chemistry 2015, 290(7):4047-4058.
10. Dong B., Wu M., Li H., Kraemer F.B., Adeli K., Seidah N.G., Park S.W., Liu J. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: Mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. Journal of Lipid Research 2010, 51(6):1486-1495.
11. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24(8):1454-1459.
12. Duranti M., Consonni A., Magni C., Sessa F., Scarafoni A. The major proteins of lupin seed: Characterisation and molecular properties for use as functional and nutraceutical ingredients. Trends in Food Science & Technology 2008, 19(12):624-633.
13. Fitzgerald K., Frank-Kamenetsky M., Shulga-Morskaya S., Liebow A., Bettencourt B.R., Sutherland J.E., Hutabarat R.M., Clausen V.A., Karsten V., Cehelsky J., Nochur S.V., Kotelianski V., Horton J., Mant T., Chiesa J., Ritter J., Munisamy M., Vaishnaw A.K., Gollob J.A., Simon A. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383(9911):60-68.
14. Girgih A.T., He R., Malomo S., Offengenden M., Wu J., Aluko R.E. Structural and functional characterization of hemp seed (Cannabis sativa L.) protein-derived antioxidant and antihypertensive peptides. Journal of Functional Foods 2014, 6:384-394.
15. Giunzioni I., Tavori H. New developments in atherosclerosis: Clinical potential of PCSK9 inhibition. Vascular Health and Risk Management 2015, 11:493-501.
16. Goldstein J.L., Brown M.S. The LDL receptor. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29(4):431-438.
17. Gu H.M., Zhang D.W. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. Journal of Biomedical Research 2015, 29(5):356-361.
18. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., Goldstein J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(21):12027-12032.
19. Jeong H.J., Lee H.S., Kim K.S., Kim Y.K., Yoon D., Park S.W. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. Journal of Lipid Research 2008, 49(2):399-409.
20. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Li Z., Liu J., Jiang J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine 2004, 10(12):1344-1351.
21. Koren M.J., Scott R., Kim J.B., Knusel B., Liu T., Lei L., Bolognese M., Wasserman S.M. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380(9858):1995-2006.
22. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., Anderson N.N., Ho Y.K., Hammer R.E., Horton J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. The Journal of Clinical Investigation 2006, 116(11):2995-3005.
23. Lambert G., Sjouke B., Choque B., Kastelein J.J., Hovingh G.K. The PCSK9 decade. Journal of Lipid Research 2012, 53(12):2515-2524.
24. Lammi C., Zanoni C., Scigliuolo G.M., D'Amato A., Arnoldi A. Lupin peptides lower low-density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory element binding protein 2 (SREBP2) pathway at HepG2 cell line. Journal of Agricultural and Food Chemistry 2014, 62(29):7151-7159.
25. Lee Y.P., Mori T.A., Puddey I.B., Sipsas S., Ackland T.R., Beilin L.J., Hodgson J.M. Effects of lupin kernel flour-enriched bread on blood pressure: A controlled intervention study. The American Journal of Clinical Nutrition 2009, 89(3):766-772.
26. Li H., Dong B., Park S.W., Lee H.S., Chen W., Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. The Journal of Biological Chemistry 2009, 284(42):28885-28895.
27. Li J., Tumanut C., Gavigan J.A., Huang W.J., Hampton E.N., Tumanut R., Suen K.F., Trauger J.W., Spraggon G., Lesley S.A., Liau G., Yowe D., Harris J.L. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. The Biochemical Journal 2007, 406(2):203-207.
28. Lindholm M.W., Elmén J., Fisker N., Hansen H.F., Persson R., Møller M.R., Rosenbohm C., Ørum H., Straarup E.M., Koch T. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Molecular Therapy: The Journal of the American Society of Gene Therapy 2012, 20(2):376-381.
29. Lo Surdo P., Bottomley M.J., Calzetta A., Settembre E.C., Cirillo A., Pandit S., Ni Y.G., Hubbard B., Sitlani A., Carfí A. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Reports 2011, 12(12):1300-1305.
30. Lovati M.R., Manzoni C., Castiglioni S., Parolari A., Magni C., Duranti M. Lupin seed gamma-conglutin lowers blood glucose in hyperglycaemic rats and increases glucose consumption of HepG2 cells. The British Journal of Nutrition 2012, 107(1):67-73.
31. Marchesi M., Parolini C., Diani E., Rigamonti E., Cornelli L., Arnoldi A., Sirtori C.R., Chiesa G. Hypolipidaemic and anti-atherosclerotic effects of lupin proteins in a rabbit model. The British Journal of Nutrition 2008, 100(4):707-710.
32. Maxwell K.N., Soccio R.E., Duncan E.M., Sehayek E., Breslow J.L. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. Journal of Lipid Research 2003, 44(11):2109-2119.
33. McNutt M.C., Lagace T.A., Horton J.D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. The Journal of Biological Chemistry 2007, 282(29):20799-20803.
34. Patten G.S., Abeywardena M.Y., Head R.J., Bennett L.E. Processed dietary plants demonstrate broad capacity for angiotensin converting enzyme and angiotensin II receptor binding inhibition in vitro. Journal of Functional Foods 2012, 4(4):851-863.
35. Pirillo A., Catapano A.L. Statin intolerance: Diagnosis and remedies. Current Cardiology Reports 2015, 17(5):27.
36. Ridker P.M., Rifai N., Bradwin G., Rose L. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. European Heart Journal 2016, 37(6):554-560.
37. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. The New England Journal of Medicine 2012, 367(20):1891-1900.
38. Ruscica M., Gomaraschi M., Mombelli G., Macchi C., Bosisio R., Pazzucconi F., Pavanello C., Calabresi L., Arnoldi A., Sirtori C.R., Magni P. Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. Journal of Clinical Lipidology 2014, 8(1):61-68.
39. Shan L., Pang L., Zhang R., Murgolo N.J., Lan H., Hedrick J.A. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochemical and Biophysical Research Communications 2008, 375(1):69-73.
40. Shantha G.P., Robinson J.G. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. Clinical Pharmacology and Therapeutics 2015, 10.1002/cpt.281.
41. Sirtori C.R., Lovati M.R., Manzoni C., Castiglioni S., Duranti M., Magni C., Morandi S., D'Agostina A., Arnoldi A. Proteins of white lupin seed, a naturally isoflavone-poor legume, reduce cholesterolemia in rats and increase LDL receptor activity in HepG2 cells. The Journal of Nutrition 2004, 134(1):18-23.
42. Sirtori C.R., Triolo M., Bosisio R., Bondioli A., Calabresi L., De Vergori V., Gomaraschi M., Mombelli G., Pazzucconi F., Zacherl C., Arnoldi A. Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. The British Journal of Nutrition 2012, 107(8):1176-1183.
43. Stein E.A., Mellis S., Yancopoulos G.D., Stahl N., Logan D., Smith W.B., Lisbon E., Gutierrez M., Webb C., Wu R., Du Y., Kranz T., Gasparino E., Swergold G.D. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. The New England Journal of Medicine 2012, 366(12):1108-1118.
44. Stein E.A., Raal F.J. Lipid-lowering drug therapy for CVD prevention: Looking into the future. Current Cardiology Reports 2015, 17(11):104.
45. Tai M.H., Chen P.K., Chen P.Y., Wu M.J., Ho C.T., Yen J.H. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Molecular Nutrition and Food Research 2014, 58(11):2133-2145.
46. Tavori H., Fan D., Blakemore J.L., Yancey P.G., Ding L., Linton M.F., Fazio S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: Evidence for a reciprocal regulation. Circulation 2013, 127(24):2403-2413.
47. Verbeek R., Stoekenbroek R.M., Hovingh G.K. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. European Journal of Pharmacology 2015, 763(Pt A):38-47.
48. Weisse K., Brandsch C., Zernsdorf B., Nkengfack Nembongwe G.S., Hofmann K., Eder K., Stangl G.I. Lupin protein compared to casein lowers the LDL cholesterol:HDL cholesterol-ratio of hypercholesterolemic adults. European Journal of Nutrition 2010, 49(2):65-71.
49. Zhang L., Song K., Zhu M., Shi J., Zhang H., Xu L., Chen Y. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. The International Journal of Neuroscience 2015, 10.3109/00207454.2015.1057636.
50. Zhang Y., Eigenbrot C., Zhou L., Shia S., Li W., Quan C., Tom J., Moran P., Di Lello P., Skelton N.J., Kong-Beltran M., Peterson A., Kirchhofer D. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. The Journal of Biological Chemistry 2014, 289(2):942-955.